Diagnose before you swap
By lead optimization, you rarely have a potency problem — you have a property problem. The discipline is to diagnose precisely which atom causes the liability, then make the smallest swap that fixes it while leaving the pharmacophore untouched. Identify the metabolic soft spot from metabolite ID, the toxic risk from a structural alert, the hERG flag from a binding assay. Aim, do not spray.
A toolkit of common fixes
Each liability has go-to swaps. A C–H being oxidized? Block it with fluorine or a bioisostere of the whole metabolized ring. A hERG liability from a basic amine in a lipophilic molecule? Lower the basic pKa, trim lipophilicity, or add polarity nearby. Poor solubility from a flat, greasy core? Hop to a less planar scaffold or replace a phenyl with a saturated ring. A reactive metabolite from an aniline or thiophene? Remove or cap the alerting group with a benign surrogate.
Liability -> Typical group swap Watch the pharmacophore
------------------- -------------------------- ------------------------
metabolic soft spot H -> F at the soft C-H; keep ring's H-bond features
O -> deactivated heteroaryl
hERG / cardiotoxicity lower amine pKa; -F on aryl; keep the cation if it binds
add polarity / cut logP
low solubility phenyl -> saturated ring; keep shape & key contacts
break flatness / add N
reactive metabolite cap aniline; swap thiophene; replace alerting atom only
remove the structural alertIt is a balancing act, not a single fix
Fixing one property often moves another. Adding fluorine to block metabolism may raise lipophilicity and reawaken a hERG risk; lowering an amine's pKa to fix hERG may hurt solubility or weaken a binding salt bridge. This is why the endgame is multiparameter optimization: you are not chasing one number but steering a profile where potency, ADME, and safety all clear their bars at once.
Pull the whole track together and the workflow is one loop: read the pharmacophore (guide 1), reach for a classical (guide 2) or non-classical (guide 3) bioisostere, hop the scaffold when the core itself is the problem (guide 4), and aim each swap at a diagnosed liability while watching the whole profile (guide 5). Same handshake, better molecule.